BR112022007725A2 - Composto, uso do composto, molécula de sirna e composição - Google Patents
Composto, uso do composto, molécula de sirna e composiçãoInfo
- Publication number
- BR112022007725A2 BR112022007725A2 BR112022007725A BR112022007725A BR112022007725A2 BR 112022007725 A2 BR112022007725 A2 BR 112022007725A2 BR 112022007725 A BR112022007725 A BR 112022007725A BR 112022007725 A BR112022007725 A BR 112022007725A BR 112022007725 A2 BR112022007725 A2 BR 112022007725A2
- Authority
- BR
- Brazil
- Prior art keywords
- compound
- composition
- conjugates
- sirna molecule
- double
- Prior art date
Links
- 108020004459 Small interfering RNA Proteins 0.000 title abstract 4
- 150000001875 compounds Chemical class 0.000 title abstract 4
- 206010000599 Acromegaly Diseases 0.000 abstract 1
- 125000005647 linker group Chemical group 0.000 abstract 1
- 108020004707 nucleic acids Proteins 0.000 abstract 1
- 150000007523 nucleic acids Chemical class 0.000 abstract 1
- 102000039446 nucleic acids Human genes 0.000 abstract 1
- 239000000126 substance Substances 0.000 abstract 1
- 238000010189 synthetic method Methods 0.000 abstract 1
- 230000008685 targeting Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
- A61K47/549—Sugars, nucleosides, nucleotides or nucleic acids
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K9/00—Peptides having up to 20 amino acids, containing saccharide radicals and having a fully defined sequence; Derivatives thereof
- C07K9/001—Peptides having up to 20 amino acids, containing saccharide radicals and having a fully defined sequence; Derivatives thereof the peptide sequence having less than 12 amino acids and not being part of a ring structure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/06—Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH
- A61P5/08—Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH for decreasing, blocking or antagonising the activity of the anterior pituitary hormones
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
- C12N15/1136—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against growth factors, growth regulators, cytokines, lymphokines or hormones
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/14—Type of nucleic acid interfering nucleic acids [NA]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/35—Nature of the modification
- C12N2310/351—Conjugate
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2320/00—Applications; Uses
- C12N2320/30—Special therapeutic applications
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Genetics & Genomics (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Molecular Biology (AREA)
- Biomedical Technology (AREA)
- General Health & Medical Sciences (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Biochemistry (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Medicinal Chemistry (AREA)
- Biophysics (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Endocrinology (AREA)
- Animal Behavior & Ethology (AREA)
- Plant Pathology (AREA)
- Physics & Mathematics (AREA)
- Microbiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Diabetes (AREA)
- Epidemiology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962925659P | 2019-10-24 | 2019-10-24 | |
| PCT/US2020/057185 WO2021081420A2 (en) | 2019-10-24 | 2020-10-23 | Conjugates and methods for treating acromegaly |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR112022007725A2 true BR112022007725A2 (pt) | 2022-08-16 |
Family
ID=75620892
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR112022007725A BR112022007725A2 (pt) | 2019-10-24 | 2020-10-23 | Composto, uso do composto, molécula de sirna e composição |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US20220288214A1 (https=) |
| EP (1) | EP4048801A4 (https=) |
| JP (1) | JP7668032B2 (https=) |
| CN (1) | CN114616339A (https=) |
| AU (1) | AU2020371736A1 (https=) |
| BR (1) | BR112022007725A2 (https=) |
| CA (1) | CA3158917A1 (https=) |
| IL (1) | IL292391A (https=) |
| WO (1) | WO2021081420A2 (https=) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA3020585A1 (en) * | 2016-04-11 | 2017-10-19 | Arbutus Biopharma Corporation | Targeted nucleic acid conjugate compositions |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2322651A1 (en) * | 2004-05-14 | 2011-05-18 | Rosetta Genomics Ltd | MicroRNAs and uses thereof |
| CA2917229A1 (en) * | 2013-07-02 | 2015-01-08 | Isis Pharmaceuticals, Inc. | Modulators of growth hormone receptor |
| BR112016022742B1 (pt) * | 2014-05-01 | 2022-06-14 | Ionis Pharmaceuticals, Inc | Composto químico, composição compreendendo o composto e uso dos mesmos |
| WO2015179693A1 (en) * | 2014-05-22 | 2015-11-26 | Isis Pharmaceuticals, Inc. | Conjugated antisense compounds and their use |
| EP3151839A4 (en) * | 2014-06-06 | 2018-02-28 | Ionis Pharmaceuticals, Inc. | Compositions and methods for enhanced intestinal absorption of conjugated oligomeric compounds |
| EP3228326A1 (en) | 2016-04-05 | 2017-10-11 | Silence Therapeutics GmbH | Nucleic acid linked to a trivalent glycoconjugate |
| DK3607069T3 (da) | 2017-04-05 | 2022-11-21 | Silence Therapeutics Gmbh | Produkter og sammensætninger |
| WO2018185253A1 (en) * | 2017-04-05 | 2018-10-11 | Silence Therapeutics Gmbh | Ligand modified double-stranded nucleic acids |
| JP7406793B2 (ja) * | 2017-06-23 | 2023-12-28 | ユニバーシティー オブ マサチューセッツ | ２テイル自己デリバリー型ｓｉＲＮＡおよび関連方法 |
| EP3775209A1 (en) * | 2018-04-05 | 2021-02-17 | Silence Therapeutics GmbH | Sirnas with at least two ligands at different ends |
-
2020
- 2020-10-23 CA CA3158917A patent/CA3158917A1/en active Pending
- 2020-10-23 WO PCT/US2020/057185 patent/WO2021081420A2/en not_active Ceased
- 2020-10-23 BR BR112022007725A patent/BR112022007725A2/pt unknown
- 2020-10-23 IL IL292391A patent/IL292391A/en unknown
- 2020-10-23 US US17/770,504 patent/US20220288214A1/en not_active Abandoned
- 2020-10-23 JP JP2022523585A patent/JP7668032B2/ja active Active
- 2020-10-23 AU AU2020371736A patent/AU2020371736A1/en not_active Abandoned
- 2020-10-23 CN CN202080075748.1A patent/CN114616339A/zh active Pending
- 2020-10-23 EP EP20879819.9A patent/EP4048801A4/en not_active Withdrawn
Also Published As
| Publication number | Publication date |
|---|---|
| CN114616339A (zh) | 2022-06-10 |
| IL292391A (en) | 2022-06-01 |
| EP4048801A4 (en) | 2023-11-22 |
| JP2022553056A (ja) | 2022-12-21 |
| WO2021081420A3 (en) | 2021-06-03 |
| JP7668032B2 (ja) | 2025-04-24 |
| EP4048801A2 (en) | 2022-08-31 |
| AU2020371736A1 (en) | 2022-06-02 |
| US20220288214A1 (en) | 2022-09-15 |
| WO2021081420A2 (en) | 2021-04-29 |
| CA3158917A1 (en) | 2021-04-29 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2024004433A (es) | Composiciones dirigidas. | |
| CY1125421T1 (el) | Ριβονουκλεϊκα οξεα που περιεχουν ν1-μεθυλο- ψευδοουρακιλες και χρησεις αυτων | |
| BR112018077362A2 (pt) | conjugados para edição de superfície de célula-alvo | |
| BR112017008976A2 (pt) | ?composição, métodos de aumento da viscosidade de composições aquosas, de tratamento de material, de produção de dextrano e reação enzimática? | |
| MX2021007376A (es) | Moléculas bifuncionales para el direccionamiento lisosómico y composiciones y métodos relacionados. | |
| BR112022010613A2 (pt) | Composto da fórmula, métodos de tratamento de fibrose hepática, de tratamento de esteatose hepática não alcoólica e de tratamento de esteatose hepática alcoólica, usos, método ou uso, molécula de sirna, composição e invenção | |
| CL2008001682A1 (es) | Metodos para el mejoramiento de plantas mediante el uso de informacion directa de secuencias de acidos nucleicos. | |
| BR112016010165A2 (pt) | composições de nucleotídeos modificados de citidina-5-carboxamida e métodos relacionados às mesmas | |
| CL2023001284A1 (es) | Composiciones y métodos para el reemplazo de alelos con adn codificado por arn | |
| AU2015329974A8 (en) | GaINAc phosphoramidites, nucleic acid conjugates thereof and their use | |
| AR105641A1 (es) | Conjugados terapéuticos de internalización celular | |
| MX2022012677A (es) | Compuestos y metodos para modular el empalme. | |
| PE20191351A1 (es) | Tratamiento aav de la enfermedad de huntington | |
| BR112017012482A2 (pt) | copolímero estático, composição, uso de um copolímero, e, métodos para liberar um ácido nucleico a uma célula ou tecido alvo e para a produção do copolímero. | |
| BR112014009066B8 (pt) | molécula de ácido nucleico, método para a sintetização de uma molécula de dna de triciclo-fosforotioato e composição farmacêutica | |
| BR112017025711A2 (pt) | ?composições, processo para preparação de siloxanos modificados por poliéter e uso das composições inovadoras? | |
| BR112013005872A2 (pt) | compostos, composição farmacêutica e respectivos usos | |
| BR112019000693A2 (pt) | composições de muc1- car e métodos para uso | |
| BR112016015105A2 (pt) | Conjugados var2csa-droga | |
| MX2024000277A (es) | Microarns modificados con 5-halouracilo y su uso en el tratamiento del cancer. | |
| BR112018010279A2 (pt) | novos anticorpos anti-emr2 e métodos de uso | |
| BR112022006476A2 (pt) | Oligonucleotídeos com análogos de nucleosídeos | |
| MX2022005330A (es) | Moleculas de union multiespecificas con scfv en el extremo nterminal. | |
| BR112016016202A2 (pt) | Construtos de direcionamento de receptores e uso dos mesmos | |
| MX374553B (es) | Derivado de ácido nucleico que tiene actividad inmunoestimuladora. |